Ozmosi | Rebamipide Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Rebamipide

Alternative Names: rebamipide, mucosta, opc-12759, opc 12759, opc12759
Clinical Status: Inactive
Latest Update: 2026-02-09
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: STAT3 Inhibitor, IL1A Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: China | Egypt | India | Indonesia | Japan | Korea | Malaysia | Pakistan | Peru | Philippines | Russia | Thailand | Ukraine | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Otsuka
Company Location:
Company Founding Year: 1921
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Esophagitis, Peptic|Stomach Ulcer|Gastroesophageal Reflux|Sjogren's Syndrome|Dry Eye Syndromes|Gastritis|Keratoconjunctivitis Sicca|Cataract|Helicobacter Infections|Dry Eye Disease|Stomach Diseases|Dyspepsia|Atrial Fibrillation

Phase 3: Keratoconjunctivitis Sicca|Dry Eye Syndromes|Stomach Ulcer|Arthritis, Rheumatoid|Spondylitis, Ankylosing|Osteoarthritis|Gastritis, Atrophic|Dyspepsia|Signs and Symptoms, Digestive|Gastritis

Phase 2: Colitis, Ulcerative|Sjogren's Syndrome|Keratoconjunctivitis Sicca|Xerostomia|Dry Eye Syndromes|Mucositis|Head and Neck Cancer|Arthritis, Rheumatoid|Stomatitis|Behcet Syndrome|Oral Ulcer|Other

Phase 1: Healthy Volunteers|Other|Dry Eye Syndromes|Keratoconjunctivitis Sicca|Gastritis|Edema

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

ChiCTR2300078984

ChiCTR2300078984

N/A

Recruiting

Gout

2024-12-31

2023-12-22

Treatments

CTR20243901

CTR20243901

N/A

Completed

Gastritis|Edema

2024-12-24

2025-04-29

Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

NCT05048069

MCTSRPMS

N/A

Unknown status

Gastritis

2024-12-15

2025-10-01

Primary Endpoints|Treatments|Trial Status

CTR20242604

CTR20242604

N/A

Completed

Gastritis|Edema

2024-09-09

2025-04-29

Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

ChiCTR2200063492

ChiCTR2200063492

N/A

Not yet recruiting

Gastritis, Atrophic

2024-08-29

CTR20240809

CTR20240809

N/A

Completed

Gastritis|Edema

2024-06-07

2025-04-29

Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

CTR20240111

CTR20240111

N/A

Completed

Edema|Gastritis

2024-02-04

2025-04-29

CTR20232354

CTR20232354

N/A

Completed

Edema|Gastritis

2024-01-29

2025-04-29

Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

CTR20232607

CTR20232607

N/A

Completed

Gastritis|Edema

2023-12-19

2025-04-29

Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

CTR20230932

CTR20230932

N/A

Completed

Gastritis|Edema

2023-06-24

2025-04-29

Patient Enrollment|Treatments

CTR20230774

CTR20230774

N/A

Completed

Gastritis|Edema

2023-05-31

2025-04-29

Patient Enrollment|Treatments

CTR20230569

CTR20230569

N/A

Completed

Edema|Gastritis

2023-05-13

2025-04-29

Patient Enrollment|Treatments

CTR20230218

CTR20230218

N/A

Completed

Edema|Gastritis

2023-04-05

2025-04-29

Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

CTR20223288

CTR20223288

N/A

Completed

Gastritis|Edema

2023-03-24

2025-04-29

Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

CTR20223436

CTR20223436

N/A

Completed

Edema|Gastritis

2023-01-16

2025-04-29

Patient Enrollment|Treatments

CTR20222377

CTR20222377

N/A

Completed

Gastritis|Edema

2023-01-06

2025-04-29

Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

CTR20222585

CTR20222585

N/A

Completed

Edema|Gastritis

2022-12-07

2025-04-29

Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

CTR20222044

CTR20222044

N/A

Completed

Edema|Gastritis

2022-10-18

2025-04-29

Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

NCT05166304

MUFMIRB App N. 1007/12/2023

P2

Completed

Arthritis, Rheumatoid

2025-08-01

2025-11-21

Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT06084624

NCT06084624

P2

Unknown status

Oral Ulcer|Behcet Syndrome

2025-01-01

2025-11-01

Primary Endpoints|Treatments|Trial Status

NCT04649697

CEBC-CU-2020-9

P3

Unknown status

Arthritis, Rheumatoid

2023-12-30

2025-10-01

Primary Endpoints|Treatments|Trial Status

NCT07397949

RVK-25-I01

P4

Not yet recruiting

Cataract|Dry Eye Syndromes|Dry Eye Disease|Keratoconjunctivitis Sicca

2026-12-01

2026-02-10

Primary Endpoints

NCT07397936

NRF-2021R1C1C1007795

P4

Completed

Dry Eye Disease|Dry Eye Syndromes|Cataract|Keratoconjunctivitis Sicca

2025-05-01

2026-02-10

Primary Endpoints|Treatments

NCT07354230

REGATA

P4

Completed

Atrial Fibrillation

2024-09-20

2026-01-22

Primary Endpoints|Treatments

NCT07297316

2022AN0535

P4

Completed

Dry Eye Disease|Dry Eye Syndromes|Keratoconjunctivitis Sicca

2024-08-30

2025-12-23

Primary Endpoints|Treatments